readthroughSign in
Oct 29, 2026Weekly roundup2 fact check notes

Bausch posts Phase 3 rifaximin cirrhosis results; pediatric plecanatide trial record updated

Rifaximin SSD missed separation from placebo in a 517-patient hepatic encephalopathy prevention study, while a 180-participant pediatric constipation trial of plecanatide remains active but not recruiting.

Bausch Health Americas had one trial post results and another trial record updated this week.

  • For the primary outcome of time to first event of overt hepatic encephalopathy requiring medical intervention or death, 22 participants in the rifaximin arm and 21 in the placebo arm had events, with a log-rank analysis showing p=0.7138.1 The study enrolled 517 participants.1
  • The status is active, not recruiting.2 The study plans to enroll approximately 180 participants at up to 30 US sites, randomized 1:1:1 to low-dose plecanatide, high-dose plecanatide, or placebo.2 The primary efficacy variable is change from baseline in spontaneous bowel movement frequency at Week 8.2

Fact check notes

  • Sentence removedRifaximin SSD-40mg IR, a Phase 3 drug for delaying hepatic encephalopathy decompensation in cirrhosis patients with medically controlled ascites, completed with results posted October 28, 2026.a figure with no citation
  • Sentence removedPlecanatide, under the brand name Trulance, is in a Phase 2b trial for functional constipation in children and adolescents aged 6 to less than 18 years, with its record last updated October 29, 2026.a figure with no citation

Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Where the check questioned a sentence, its note is shown above. Not investment advice.